Business
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update
Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of
About this update from Senseonics Holdings, Inc.
[{"type":"text","content":"Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudited fourth quarter 2025 revenue of approximately $14.2 million, an increase of 71% year-over-year, and preliminary unaudited revenue of approximately $35.2 million, an increase of approximately 57% year-over-year, representing largest quarterly and annual revenue in company history.Achieved 103% new patient growth in the U.S. in the fourth quarter versus the same period in 2024, driven largely by positive returns from direct-to-consumer (DTC) marketing efforts and representing the largest new patient addition in company history.Secured Investigational Device Exemption (IDE) approval from the FDA to commence a pivotal trial for the self-powered battery enabled Gemini sensor and enrolled the first patients in the trial.First commercial patients using pump partner Sequel’s twiist™ insulin delivery system with Eversense 365 compatibility.Executed agreements with Ascensia Diabetes Care to take over commercialization and distribution of Eversense®, beginning January 1, 2026 in the U.S. “We closed a successful 2025 on a high note, achieving by far our highest revenue quarter as our DTC efforts continue to drive an increasing number of patients to the world’s first and only year-long CGM, said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We now look ahead to a 2026 that should bring more exciting developments for Senseonics, most notably the transition of commercial and distribution rights to Eversense 365 from Ascensia, which we expect will lead to higher revenue and improved gross margins. We also expect a boost from an anticipated CE mark in Europe for Eversense 365, the launch of the twiist system with full Eversense compatibil...